Casa Di Cura Abano Terme Polispecialistica E Termale S.p.A. Con Sigla Casa Di Cura Abano Terme S.p.A.
- Address
- lock Available on a paid plan
Neoplasms and Urologic Oncology
The research at Casa Di Cura Abano Terme Polispecialistica E Termale S.p.A. includes clinical trials in neoplasms, with a focus on high-risk localized and locally advanced prostate cancer. These studies are designed to assess whether adding new treatment approaches to standard care can improve disease control and support better outcomes for patients undergoing treatment.
- Studying prostate cancer care in patients with high-risk or locally advanced disease
- Evaluating the effectiveness of a new therapy added to standard hormonal treatment
- Exploring whether the approach can improve cancer response and reduce the chance of progression
This work reflects a strong interest in advancing urology and cancer treatment through better therapeutic options and improved imaging-based assessment.
Skin and Connective Tissue Diseases and Wound Care
Another area of research at this hospital involves skin and connective tissue diseases, especially diabetic foot ulcer management. The trial activity focuses on testing whether an added treatment can be safe and well tolerated while also helping to improve healing in people with chronic foot wounds related to diabetes.
- Focusing on diabetic foot ulcers, a serious complication of diabetes
- Assessing safety and tolerability of a new treatment alongside standard care
- Looking at whether the therapy may support better wound healing and ulcer recovery
These studies highlight the site’s interest in practical wound care research aimed at improving treatment options for patients with difficult-to-heal ulcers.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Mimetech S.r.l.1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Casa Di Cura Abano Terme Polispecialistica E Termale S.p.A. Con Sigla Casa Di Cura Abano Terme S.p.A.
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Udonitrectag (MT8) in Combination with Standard Care for Safety and Pharmacokinetics in Diabetic Foot Ulcer Treatment | Mimetech S.r.l. | Phase I/II | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 4 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Apalutamide | 1 | Unknown | 2019-07-11 | 2019-07-11 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.